When.com Web Search

  1. Ads

    related to: how expensive is crispr treatment for sale near me

Search results

  1. Results From The WOW.Com Content Network
  2. FDA approves cure for sickle cell disease, the first ... - AOL

    www.aol.com/news/fda-approves-cure-sickle-cell...

    December 8, 2023 at 1:19 PM. The Food and Drug Administration on Friday approved a powerful treatment for sickle cell disease, a devastating illness that affects more than 100,000 Americans, the ...

  3. Exagamglogene autotemcel - Wikipedia

    en.wikipedia.org/wiki/Exagamglogene_autotemcel

    DrugBank. DB15572. UNII. S53L777GM8. KEGG. D12749. Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease [1][3] and transfusion-dependent beta thalassemia. [1] It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

  4. FDA Approves First CRISPR Treatment in U.S. - AOL

    www.aol.com/fda-approves-first-crispr-treatment...

    Now, on Dec. 8, the U.S. Food and Drug Administration (FDA) approved the very first treatment in the country based on the technology. In the medical world, that’s lightning speed.

  5. FDA considers first CRISPR gene editing treatment that may ...

    www.aol.com/fda-considers-first-crispr-gene...

    If approved, exa-cel, made by Boston-based Vertex Pharmaceuticals and the Swiss company CRISPR Therapeutics, would be the first FDA-approved treatment that uses genetic modification called CRISPR.

  6. CRISPR gene editing - Wikipedia

    en.wikipedia.org/wiki/CRISPR_gene_editing

    The CRISPR treatment for LCA10 (the most common variant of Leber congenital amaurosis which is the leading cause of inherited childhood blindness) modifies the patient's defective photoreceptor gene. In March 2020, the first patient volunteer in this US-based study, sponsored by Editas Medicine , was given a low-dose of the treatment to test ...

  7. CRISPR - Wikipedia

    en.wikipedia.org/wiki/CRISPR

    The CRISPR-Cas9 system has been shown to make effective gene edits in Human tripronuclear zygotes, as first described in a 2015 paper by Chinese scientists P. Liang and Y. Xu. The system made a successful cleavage of mutant Beta-Hemoglobin (HBB) in 28 out of 54 embryos.